Stock Market News
Diurnal Group expects admission of new shares amid product launch funding
Pharmaceutical company Diurnal on Tuesday announced the expected admission of a slew of new shares this week as the company raises funds for operations including the launch of its Alkindi product in Europe.
Application had been made for 1,632,882 EIS/VCT shares to be admitted to trading on the London stock exchange, which was expected for 0800 BST on Wednesday, which the company said would be followed by an additional 3,893,432 general shares and 3,229,575 convertible loan shares on the next day.
On 14 March, the company announced its intention to raise £11m through the placing as it seeks to fund a variety of operations.
Alkindi had the potential to become the first licenced hydrocortisone product in Europe specifically designed for use in children with adrenal insufficiency.
Aside from completing development of Alkindi and launching the product in Europe, the funds would be utilised to complete the European development of Chronocort, a hydrocortisone product intended to closely mimic the cortisol circadian rhythm.
A pivotal phase III study in the US for Chronocort was also set to start, with an expansion into adrenal insufficiency via a phase II clinical trial anticipated to start later this year.
Following the second admission on Thursday, the total issued share capital will have increased to 61,336,523 ordinary shares of £0.05 each, with each ordinary share continuing to carry the right to one vote.
As of 1505 BST Diurnal Group's shares were unchanged at 199.00p.
Application had been made for 1,632,882 EIS/VCT shares to be admitted to trading on the London stock exchange, which was expected for 0800 BST on Wednesday, which the company said would be followed by an additional 3,893,432 general shares and 3,229,575 convertible loan shares on the next day.
On 14 March, the company announced its intention to raise £11m through the placing as it seeks to fund a variety of operations.
Alkindi had the potential to become the first licenced hydrocortisone product in Europe specifically designed for use in children with adrenal insufficiency.
Aside from completing development of Alkindi and launching the product in Europe, the funds would be utilised to complete the European development of Chronocort, a hydrocortisone product intended to closely mimic the cortisol circadian rhythm.
A pivotal phase III study in the US for Chronocort was also set to start, with an expansion into adrenal insufficiency via a phase II clinical trial anticipated to start later this year.
Following the second admission on Thursday, the total issued share capital will have increased to 61,336,523 ordinary shares of £0.05 each, with each ordinary share continuing to carry the right to one vote.
As of 1505 BST Diurnal Group's shares were unchanged at 199.00p.
Related share prices |
---|
Diurnal Group (DNL) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price